Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
- Conditions
- Gastric and Gastroesophageal Junction Carcinoma
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05251948
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, China
🇨🇳Affiliated Hopsital of Jining Medical University, Jining, China
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT04665843
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇿Fakultni nemocnice v Motole, Praha 5, Czechia
🇫🇷Centre Francois Baclesse, Caen, France
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT04665856
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Conditions
- Advanced Unresectable or Metastatic Solid Malignancy
- Interventions
- Drug: EntrectinibDrug: InavolisibDrug: AlectinibDrug: IpatasertibDrug: AtezolizumabDrug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxfDrug: PralsetinibDrug: Investigator's Choice of ChemotherapyDrug: Trastuzumab EmtansineDrug: TucatinibDrug: PaclitaxelDrug: Tiragolumab
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04632992
- Locations
- 🇺🇸
Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 760
- Registration Number
- NCT04543617
- Locations
- 🇺🇸
MD Anderson Cancer Center; Oncology, Houston, Texas, United States
🇿🇦Limpopo Cancer Research Institute, Polokwane, South Africa
🇺🇸Compassionate Cancer Care Medical Group, Inc, Corona, California, United States
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 620
- Registration Number
- NCT04294810
- Locations
- 🇺🇸
US oncology research at Minnesota Oncology, Saint Paul, Minnesota, United States
🇺🇸Onc & Hem Assoc SW Virginia, Salem, Virginia, United States
🇦🇺Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT04256421
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸SCRI Florida Cancer Specialists North, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Inst., Nashville, Tennessee, United States
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Conditions
- Urothelial CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 272
- Registration Number
- NCT03869190
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇬🇷Attiko Hospital University of Athens, Athens, Greece
🇬🇷Athens Medical Center, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.